High Gross MarginsAn ~83% gross margin indicates the product technology commands strong per-unit economics in specialty chemical/animal nutrition end-markets. High gross margins create durable opportunity for operating leverage as revenue scales, improving the pathway to sustained profitability if SG&A and R&D are controlled.

Revenue Growth TractionPositive ~15% YoY revenue growth shows commercial adoption beyond pilot stages and validates market demand for phenylcapsaicin applications. If this trend continues, it supports leveraging fixed costs and improving operating margins over the next several quarters as product placements expand in animal nutrition.

Debt-free Balance Sheet And Equity BaseA debt-free balance sheet and ~70.1M equity provide structural financial flexibility to fund commercialization and R&D without immediate refinancing pressure. This reduces solvency risk and gives management time to reach cash break-even or raise capital on more favorable terms over 2–6 months.

Bears Say

Deep And Persistent UnprofitabilityA net margin near -208% and negative EBIT/EBITDA reflect a cost base far exceeding current revenues. Absent rapid revenue scale or cost restructuring, persistent losses can erode equity, limit reinvestment capacity, and force dilutive financings, threatening long-term viability if profitability remains out of reach.

Consistent Negative Operating And Free Cash FlowOngoing negative OCF and FCF (~-11.5M) mean operations do not self-fund growth, creating reliance on external funding or reserves. Over a multi-month horizon this raises dilution and execution risk, as sustained cash burn can constrain commercialization investments and slow market expansion.

Negative Returns On EquityA ~-25% ROE signals the company is destroying shareholder capital rather than creating it. Persistently negative ROE undermines investor confidence and can make future capital raises more costly, limiting ability to scale operations and commercialize products without significant strategic change.

aXichem AB Class A News

aXichem AB Class A (A6X) Q1 Earnings Cheat Sheet

aXichem AB Class A (A6X) is scheduled to report 1st quarter earnings on 05/22/2024. Regarding Q1 estimates, Wall...

2y ago

A6X

A6X Upcoming Earnings Report: What to Expect?

aXichem AB Class A (A6X) is scheduled to report 3rd quarter earnings on 11/22/2023. Regarding Q3 estimates, Wall...

2y ago

A6X

AXIC.A FAQ

What was aXichem AB Class A’s price range in the past 12 months?

aXichem AB Class A lowest stock price was kr0.97 and its highest was kr4.07 in the past 12 months.

What is aXichem AB Class A’s market cap?

aXichem AB Class A’s market cap is kr90.53M.

When is aXichem AB Class A’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were aXichem AB Class A’s earnings last quarter?

Currently, no data Available

Is aXichem AB Class A overvalued?

According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does aXichem AB Class A pay dividends?

aXichem AB Class A does not currently pay dividends.

What is aXichem AB Class A’s EPS estimate?

aXichem AB Class A’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does aXichem AB Class A have?

aXichem AB Class A has 67,559,880 shares outstanding.

What happened to aXichem AB Class A’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of aXichem AB Class A?

Currently, no hedge funds are holding shares in SE:AXIC.A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

aXichem AB Class A

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.